RecruitingNCT06656715

Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure

Sponsor

M.D. Anderson Cancer Center

Enrollment

100 participants

Start Date

Dec 16, 2024

Study Type

OBSERVATIONAL

Conditions

To describe and compare the symptom burden in cancer patients with concurrent diagnosis of heart failure (HFrEF compared to HFpEF).

Min Age: 18 Years

Age 18 years and older
Individuals with a concurrent solid tumor cancer diagnosis
Not receiving active cancer treatment except for those on maintenance (i.e., Selective ER modulators (SERMs)\[Tamoxifen\], Aromatase inhibitors (Anastrozole, Letrozole, Exemestane), Ovarian suppression therapy (GnRH Agonists \[Leuprolide\], Androgen deprivation therapy for prostate cancer
Completed cancer treatment at least 3 months and up to 3 years before study enrollment.
Therapy
Able to read, speak and consent in English
Ability to understand and the willingness to sign a written informed consent document
Diagnosis of heart failure, confirmed by echocardiogram, MUGA, or cardiac catheterization
Internet access via smart phone, tablet, a computer, or another device with the capacity to 1) download the Fitbit App and 2) complete electronic study assessments via REDCap.

Participants undergoing active cancer treatment.
Inability to provide consent in the medical record, such as cognitively impaired individuals.

The University of Texas of MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06656715